These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 10430068

  • 1. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma.
    Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, Mok TS, Yeo W, Liew CT, Leung NW, Tang AM, Johnson PJ.
    Clin Cancer Res; 1999 Jul; 5(7):1676-81. PubMed ID: 10430068
    [Abstract] [Full Text] [Related]

  • 2. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, Johnson PJ.
    Cancer; 2002 Jan 15; 94(2):421-7. PubMed ID: 11905412
    [Abstract] [Full Text] [Related]

  • 3. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
    Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ.
    J Natl Cancer Inst; 2005 Oct 19; 97(20):1532-8. PubMed ID: 16234567
    [Abstract] [Full Text] [Related]

  • 4. Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma.
    Kaseb AO, Shindoh J, Patt YZ, Roses RE, Zimmitti G, Lozano RD, Hassan MM, Hassabo HM, Curley SA, Aloia TA, Abbruzzese JL, Vauthey JN.
    Cancer; 2013 Sep 15; 119(18):3334-42. PubMed ID: 23821538
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
    Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K.
    Cancer Chemother Pharmacol; 2004 Nov 15; 54(5):385-90. PubMed ID: 15248028
    [Abstract] [Full Text] [Related]

  • 6. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma.
    Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M.
    World J Gastroenterol; 2005 Apr 28; 11(16):2526-9. PubMed ID: 15832431
    [Abstract] [Full Text] [Related]

  • 7. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH, Sirott M, Saltz L, Heelan R, Huang Y, Keresztes R, Kelsen DP.
    Cancer; 1995 May 01; 75(9):2197-202. PubMed ID: 7712428
    [Abstract] [Full Text] [Related]

  • 8. A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma.
    Seki S, Yamada T, Kawakita N, Masuichi H, Kitada T, Sakaguchi H.
    Hepatogastroenterology; 2003 May 01; 50(53):1598-602. PubMed ID: 14571794
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma.
    Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL.
    Hepatogastroenterology; 2004 May 01; 51(57):815-9. PubMed ID: 15143923
    [Abstract] [Full Text] [Related]

  • 10. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC.
    Scand J Gastroenterol; 2009 May 01; 44(12):1477-86. PubMed ID: 19958061
    [Abstract] [Full Text] [Related]

  • 11. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy.
    Akçali Z, Akin E, Ozyilkan O.
    Cancer; 2002 Nov 01; 95(9):2038-9; author reply 2039. PubMed ID: 12404300
    [No Abstract] [Full Text] [Related]

  • 12. Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
    Patt YZ, Hassan MM, Lozano RD, Waugh KA, Hoque AM, Frome AI, Lahoti S, Ellis L, Vauthey JN, Curley SA, Schnirer II, Raijman I.
    Clin Cancer Res; 2001 Nov 01; 7(11):3375-80. PubMed ID: 11705850
    [Abstract] [Full Text] [Related]

  • 13. Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center.
    Abrams RA, Pajak TF, Haulk TL, Flam M, Asbell SO.
    Cancer J Sci Am; 1998 Nov 01; 4(3):178-84. PubMed ID: 9612600
    [Abstract] [Full Text] [Related]

  • 14. Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: a communication.
    Patt YZ, Hoque A, Roh M, Ellis L, Lozano R, Carrasco CH, Charnsangavej C, Cleary K.
    Am J Clin Oncol; 1999 Apr 01; 22(2):209-13. PubMed ID: 10199464
    [Abstract] [Full Text] [Related]

  • 15. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma.
    Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L.
    Hematol Oncol Stem Cell Ther; 2008 Apr 01; 1(3):159-65. PubMed ID: 20063546
    [Abstract] [Full Text] [Related]

  • 16. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma.
    Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S.
    Oncology; 2011 Apr 01; 81(5-6):281-90. PubMed ID: 22133996
    [Abstract] [Full Text] [Related]

  • 17. A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma.
    Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C.
    Cancer; 2005 Feb 15; 103(4):756-62. PubMed ID: 15637692
    [Abstract] [Full Text] [Related]

  • 18. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee DY, Chon CY, Moon YM, Han KH.
    Cancer; 2007 Jul 01; 110(1):129-37. PubMed ID: 17508408
    [Abstract] [Full Text] [Related]

  • 19. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study.
    Hong RL, Sheen TS, Ko JY, Hsu MM, Wang CC, Ting LL.
    Br J Cancer; 1999 Aug 01; 80(12):1962-7. PubMed ID: 10471046
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis.
    Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ.
    Cancer; 2000 May 01; 88(9):1986-91. PubMed ID: 10813709
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.